Chargement en cours...
Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin
Cardiotoxicity represents the major side-effect limiting the clinical use of anthracyclines, especially doxorubicin, in cancer chemotherapy. The use of non-toxic prodrugs, or of liposome-encapsulated drugs, allows a better targeting of the tumours and may, therefore, improve the tolerance to the tre...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Nature Publishing Group
1999
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2374342/ https://ncbi.nlm.nih.gov/pubmed/10487608 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6690646 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|